================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                               -------------------


                                    FORM 10-Q

[X]      QUARTERLY  REPORT  PURSUANT  TO SECTION  13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

                   For the Fiscal Quarter Ended June 30, 1999

[ ]      TRANSITION  REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

               For the Transition period from _____ to _________.



                         Commission file number: 0-27596



                                 CONCEPTUS, INC.
             (Exact name of Registrant as specified in its charter)



               Delaware                                      94-3170244
   (State or other jurisdiction of                       (I.R.S. Employer
    incorporation or organization)                      Identification No.)

                               1021 Howard Avenue
                              San Carlos, CA 94070
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (650) 802-7240

                               -------------------


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for at least the past 90 days.

                             Yes  X      No
                                -----      -----

As of June 30,  1999,  9,629,150  shares of the  Registrant's  Common Stock were
outstanding.

================================================================================


<PAGE>

<TABLE>

                                 CONCEPTUS, INC.

                  FORM 10-Q For the Quarter Ended June 30, 1999

                                      INDEX

<CAPTION>
                                                                                                                Page
<S>            <C>                                                                                              <C>
               Facing sheet                                                                                      1

               Index                                                                                             2

Part I.        Financial Information

Item 1.        a)     Consolidated balance sheets at June 30, 1999 and December 31, 1998                         3

               c)     Consolidated statements of operations for the three and six month periods ended June
                      30, 1999 and June 30, 1998                                                                 4

               c)     Consolidated statements of cash flows for the six month periods ended June 30, 1999
                      and June 30, 1998                                                                          5

               d)     Notes to consolidated financial statements                                                 6

Item 2.        Management's Discussion and Analysis of Financial Condition and Results of Operations             7

Item 3.        Quantitative and Qualitative Disclosures About Market Risk                                        10

Part II.       Other Information                                                                                 11

               Signature                                                                                         12

               Index to Exhibits                                                                                 13

</TABLE>

                                       2


<PAGE>

                          PART I: FINANCIAL INFORMATION

ITEM 1.  Financial Statements

                                 Conceptus, Inc.

<TABLE>
                           Consolidated Balance Sheets
               (In thousands, except share and per share amounts)


<CAPTION>
                                                                           June 30, 1999       December 31, 1998
                                                                           -------------       -----------------
Assets                                                                      (Unaudited)              (Note 1)

  Current assets:
<S>                                                                           <C>                  <C>
    Cash and cash equivalents                                                 $ 10,677             $ 11,503
    Short-term investments                                                       3,981                5,568
    Accounts receivable, net                                                        21                  139
    Other current assets                                                           220                   65
                                                                              --------             --------

  Total current assets                                                          14,899               17,275

  Property and equipment, net                                                    1,069                1,391

  Other assets                                                                     317                  365
                                                                              --------             --------

                                                                              $ 16,285             $ 19,031
                                                                              ========             ========

Liabilities and stockholders' equity
  Current liabilities:
    Accounts payable                                                          $    261             $    165
    Accrued compensation                                                           191                  421
    Other accrued liabilities                                                       67                   92
    Current portion of deferred revenue                                             97                   97
                                                                              --------             --------

  Total current liabilities                                                        616                  775

  Long-term portion of deferred revenue                                            186                  242

  Stockholders' equity:
    Common stock, $0.003 par value, 30,000,000 shares authorized,               63,573               63,570
      9,629,150 and 9,620,205 shares issued and outstanding at
        June 30, 1999 and December 31, 1998, respectively
    Stockholder notes receivable                                                   (54)                 (54)
    Deferred compensation                                                          (59)                (106)
    Accumulated deficit                                                        (47,977)             (45,396)
                                                                              --------             --------

  Total stockholders' equity                                                    15,483               18,014
                                                                              --------             --------

                                                                              $ 16,285             $ 19,031
                                                                              ========             ========
<FN>

                See notes to consolidated financial statements.
</FN>
</TABLE>

                                       3
<PAGE>


<TABLE>

                                          Conceptus, Inc.

                               Consolidated Statements of Operations
                                            (unaudited)
                              (In thousands, except per share amounts)

<CAPTION>
                                                       Three Months Ended        Six Months Ended
                                                            June 30,                  June 30,
                                                    -----------------------   --------------------
                                                       1999         1998         1999         1998
                                                     -------      -------      -------      -------
<S>                                                  <C>          <C>          <C>          <C>
Net sales                                            $    38      $    85      $    68      $   252
Cost of sales                                             44          676           84        1,512
                                                     -------      -------      -------      -------

Gross profit (loss)                                       (6)        (591)         (16)      (1,260)

Operating expenses:
  Research and development                             1,013        1,563        1,751        2,949
  Selling, general and administrative                    710        2,042        1,262        3,819
                                                     -------      -------      -------      -------

Total operating expenses                               1,723        3,605        3,013        6,768
                                                     -------      -------      -------      -------

Operating loss                                        (1,729)      (4,196)      (3,029)      (8,028)

Interest and investment income, net                      230          333          448          709
                                                     -------      -------      -------      -------

Net loss                                             $(1,499)     $(3,863)     $(2,581)     $(7,319)
                                                     =======      =======      =======      =======

Basic and diluted net loss per share                 $ (0.16)     $ (0.41)     $ (0.27)     $ (0.77)
                                                     =======      =======      =======      =======

Shares used in computing basic
  and diluted net loss per share                       9,626        9,517        9,623        9,510
                                                     =======      =======      =======      =======
<FN>

                See notes to consolidated financial statements.
</FN>
</TABLE>

                                                 4
<PAGE>


<TABLE>
                                           Conceptus, Inc.

                                Consolidated Statements of Cash Flows
                                             (Unaudited)
                          Increase (Decrease) in Cash and Cash Equivalents
                                           (In thousands)

<CAPTION>
                                                                          Six Months Ended
                                                                              June 30,
                                                                   ------------------------------
                                                                        1999              1999
                                                                   ------------      ------------
<S>                                                                   <C>               <C>
Cash flows used in operating activities
Net loss                                                              $ (2,581)         $ (7,319)

Adjustments to reconcile net loss to net cash
from (used in) operating activities:
        Depreciation and amortization                                      331               346
        Amortization of deferred compensation                               47                52
        Recognition of deferred revenue                                    (56)              (49)
        Changes in operating assets and liabilities:
             Accounts receivable                                           118               468
             Note receivable                                                 -              (256)
             Inventory                                                       -               355
             Other current assets                                         (155)              (18)
             Accounts payable                                               96              (296)
             Accrued compensation                                         (230)              512
             Other accrued liabilities                                     (25)              (14)
                                                                   ------------      ------------

Net cash used in operating activities                                   (2,455)           (6,219)
                                                                   ------------      ------------

Cash flows provided by investing activities
Purchase of investments                                                      -           (18,522)
Maturities of investments                                                1,587            27,055
Capital expenditures                                                        (9)             (718)
Change in other assets                                                      48                13
                                                                   ------------      ------------

Net cash provided by investing activities                                1,626             7,828
                                                                   ------------      ------------

Cash flows provided by financing activities
Proceeds from issuance of common stock                                       3                40
Principal payments on debt and capital obligations                           -               (26)
                                                                   ------------      ------------

Net cash provided by financing activities                                    3                14
                                                                   ------------      ------------

Net change in cash and cash equivalents                                   (826)            1,623
Cash and cash equivalents at beginning of period                        11,503             9,250
                                                                   ------------      ------------
Cash and cash equivalents at end of period                             $10,677           $10,873
                                                                   ============      ============

<FN>

                 See notes to consolidated financial statements.
</FN>
</TABLE>

                                        5
<PAGE>



                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                    Unaudited

Note 1.  Summary of Significant Accounting Policies

Method of Preparation

         The accompanying consolidated balance sheet as of June 30, 1999 and the
consolidated statements of operations and cash flows for the three and six month
periods  ended June 30,  1999 and 1998 have been  prepared  by  Conceptus,  Inc.
("Conceptus" or the "Company"), without audit. In the opinion of management, all
adjustments,  consisting  only of normal  recurring  adjustments,  necessary  to
present fairly the financial position,  results of operations, and cash flows at
June 30, 1999, and for all periods presented,  have been made. The balance sheet
as of December 31, 1998 has been derived from audited financial statements as of
that date.

         Although  the  Company   believes   that  the   disclosures   in  these
consolidated financial statements are adequate to make the information presented
not  misleading,  certain  information  and  footnote  disclosures  required  by
Generally Accepted Accounting  Principles for complete financial statements have
been  omitted  pursuant  to the  rules and  regulations  of the  Securities  and
Exchange  Commission  ("SEC").   This  financial  data  should  be  reviewed  in
conjunction with the audited financial  statements and notes thereto included in
the  Company's  Form 10-K for the year ended  December 31, 1998.  The results of
operations for the three and six months ended June 30, 1999 may not  necessarily
be indicative of the operating results for the full 1999 fiscal year.

Computation of Net Loss Per Share

         Basic  earnings per share is computed using net income and the weighted
average number of common shares outstanding during the period.  Diluted earnings
per share is computed using net income and the weighted average number of common
and dilutive common equivalent shares outstanding during each period.  Under the
requirements for calculating basic earnings per share, the effect of potentially
dilutive  securities  such as stock  options is excluded.  Basic and diluted net
loss is computed  using the  weighted  average  number of shares of common stock
outstanding.

Comprehensive Income

         During  the  first  and  second  quarters  of  1999  and  1998,   total
comprehensive  income  (loss)  was the same as net income  (loss) as  unrealized
gains and losses were immaterial.


Item 2. Management's  Discussion and Analysis of Financial Condition and Results
of Operations

         The  following  discussion  should  be read  in  conjunction  with  the
unaudited  financial  statements and notes thereto  included in Part I-Item 1 of
this  Quarterly  Report.  In  addition,  except  for the  historical  statements
contained therein, the following discussion contains forward-looking  statements
within the meaning of Section 21E of the  Securities  Exchange  Act of 1934,  as
amended.  The Company  wishes to alert readers that the factors set forth in the
Company's  Annual  Report on Form 10-K for the year ended  December 31, 1998, as
well as other  factors,  including  those set forth in the following  discussion
could in the future affect, and in the past have affected,  the Company's actual
results  and could  cause the  Company's  results  for future  periods to differ
materially from those expressed in any forward-looking  statements made by or on
behalf of the Company.

                                       6
<PAGE>

Overview

         Since  inception on September 18, 1992,  Conceptus  has been  primarily
engaged in the design,  development  and marketing of innovative  interventional
medical devices for use in reproductive medicine. Currently, the Company's focus
is to develop a non-surgical approach to female sterilization, the most commonly
performed contraceptive  procedure worldwide.  The Company has a limited history
of operations and has experienced  significant operating losses since inception.
Operating losses are expected to continue for at least the next several years as
the Company continues to expend substantial resources to fund clinical trials in
support of regulatory and  reimbursement  approvals and to conduct  research and
product development.

         The  Company  continues  to progress in its  development  and  clinical
efforts  of  the  S/TOP(TM)  non-surgical  permanent  contraceptive  device.  As
previously announced,  Conceptus  demonstrated clinical feasibility of the S/TOP
device in May 1999 when 60  woman-months  of efficacy  data was obtained with no
pregnancies. As of August 5, 1999, woman-months of efficacy has increased to 114
and based on this sample data,  statistical  calculations  estimate  that if the
S/TOP device had no  contraceptive  effect  there would have been  approximately
nine  pregnancies  as of July 31, 1999.  There have been no  pregnancies  in the
S/TOP phase II study to date.  S/TOP devices have been placed in 61 patients who
are  continuing in the Phase II clinical  trial,  and of these,  36 patients are
relying  on the S/TOP  device  for  contraception.  Additionally,  all  patients
relying  on the  S/TOP  device  have  been  confirmed  to have  bilateral  tubal
occlusion by hysterosalpingogram at the three-month post-placement  examination.
The  remaining 25 patients  have not yet  completed  the  three-month  follow-up
examination to enable reliance on the S/TOP device.

         The  S/TOP   procedure  is  designed  to  be  a  permanent   method  of
contraception  capable  of  being  place  in  an  office  setting  with  minimal
discomfort. To support the feasibility of an office based placement, the Company
is collecting data in its Phase II trial regarding the time required to complete
the procedure, the use of analgesia and/or anesthesia,  patient tolerance of the
placement  procedure,  and patient  tolerance  of wearing  the device.  With the
introduction of the gamma design in November,  1998,  average procedure time has
decreased below 29 minutes. A significant  majority of the placement  procedures
were performed without general anesthesia, and of the patients wearing the gamma
design,  91% have reported  "good" to  "excellent"  tolerance of the  procedure.
Total wear data has increased to 300 woman-months and there has been a low level
of anticipated adverse events.

         In 53 cases in which a gamma  device was placed,  there have been three
adverse events,  which the Company believes were a result of technical  failures
and  investigator  learning  curve.  Two of these  patients have exited from the
study and the third patient is continuing in the study.  In each of these cases,
device  placement  did not meet study  protocol  requirements  and  resulted  in
endoscopic  device  retrieval  from the  abdomen or uterus.  Because  the proper
placement  of the S/TOP device is a critical  component of the S/TOP  procedure,
the Company is implementing device changes and has revised physician training in
order to  minimize  the  possibility  of improper  placement.  While the Company
believes  that  the  incidence  of  improper  placement  can  be  managed  to an
insignificant  level,  the possibility of improper  placement cannot be entirely
eliminated.

         In  addition  to the  Company's  on-going  Phase II trial,  the Company
continues to perform pre-hysterectomy studies to support the Company's theorized
mechanism  of  contraception  of the S/TOP  device.  The  Company  believes  the
contraceptive effect of the S/TOP device is a result of the space-filling design
of the device in combination  with a local benign tissue response to the device.
These effects  mechanically  alter the tubal architecture and interfere with the
function of the normal  fallopian tube. As of May 1999,  histology  analysis has
been performed on 35 fallopian tubes in which the S/TOP device was placed


                                       7

<PAGE>

for an average of nine weeks  prior to  removal  of the  uterus.  This  analysis
demonstrated that the S/TOP device has become  completely  incorporated into the
fallopian tube tissue with a  proliferation  of smooth muscle cells and fibrotic
tissue interlaced throughout the device. Additionally, the response was noted to
be localized to the device with no reaction beyond the S/TOP device.

         Conceptus continues to formulate a Phase III clinical trial to commence
in the first half of 2000 in  approximately  ten sites in the United  States and
other appropriate countries.  The Company plans to place devices in a sufficient
number of patients with an  appropriate  amount of follow-up data to demonstrate
what the  Company  believes is an efficacy  rate that is  sufficient  for market
acceptance.  In support of this plan, the Company plans to submit to the FDA and
other  regulatory  bodies in the fourth quarter of 1999,  data from its Phase II
trial and histology  analysis from  pre-hysterectomy  patients.  There can be no
assurance,  however, that the Company's efforts to obtain approvals from the FDA
and other regulatory bodies to commence a Phase III trial will be successful and
there can be no assurance  that ultimate  Phase III approval,  if ever obtained,
will not require more  clinical data than that which is available at the time of
the Company's initial request.

         Based on the  current  and future  Phase II  clinical  data the Company
plans to freeze  the Phase II  database  in  September  1999 and  actively  seek
approval  from the FDA and  other  regulatory  bodies  to  commence  a Phase III
clinical  trial in the first half of 2000.  Thus,  the Company plans to increase
the level of its  expenditures on product  development,  regulatory and clinical
activities,  and administrative support in pursuit of completion of Phase II and
Phase III clinical trials.  The Company will need to raise additional funding to
prepare and execute a market  release of the S/TOP  device.  Toward this end the
Company  is  actively  seeking an  appropriate  sales and  marketing  partner to
prepare for a  significant  market launch of the S/TOP device upon approval from
the FDA and other regulatory bodies. The failure to secure necessary  regulatory
approvals,  the failure to secure a partner or the failure to secure  additional
funding will  adversely  affect the Company.  There can be no assurance that the
Company will be successful in these efforts.

         In  July  1998,  the  Company  effected  a  major  restructuring  which
eliminated all sales and marketing personnel,  the manufacturing  function,  and
significantly   reduced   administrative   overhead.   As  a   result   of  this
restructuring,  the Company  continues to seek sales and  marketing  partners to
distribute its current products,  the ERA and FUTURA Resectoscope  Sleeves,  the
STARRT Falloposcopy  system, and T-TAC products.  While the Company is committed
to establishing  an effective  distribution  channel for its existing  products,
there can be no  assurance  that the Company will be  successful  in doing so as
there is no proven distribution  channel for marketing the Company's products in
the United States or internationally.

         Some of the Company's  products are currently  manufactured  by certain
original equipment  manufacturers  while others are manufactured by Conceptus at
its  location  in San  Carlos,  California.  The  Company  is  also  seeking  to
out-source the manufacturing of its STARRT, ERA and FUTURA products.

         Future  revenues and results of operations may fluctuate  significantly
from quarter to quarter and will depend upon,  among other factors,  the ability
to attract marketing  partners and out-source  manufacturing,  the rate at which
the Company establishes its domestic and international distribution network, the
timing and size of  distributor  purchases,  actions  relating to regulatory and
reimbursement  matters,  the extent to which the Company's  products gain market
acceptance, the progress of clinical trials, and the introduction of competitive
products for diagnosis and treatment of the female reproductive system.


                                       8

<PAGE>


Results of Operations - Three and Six Months Ended June 30, 1999 and 1998

         Sales  decreased  to $38,000  and  $68,000 for the three and six months
ended June 30,  1999,  respectively,  from  $85,000  and  $252,000  for the same
periods  in the  prior  year.  The  55%  and 73%  decreases,  respectively,  are
primarily due to lower unit  shipments of the Company's  T-TAC and ERA products.
It is  anticipated  that  revenues  will  continue to decrease  during the third
quarter  of  1999  as the  Company  focuses  its  efforts  on the  research  and
development  of  its  S/TOP  permanent   contraceptive  device.  Domestic  sales
comprised 100% of sales for the three and six month periods ended June 30, 1999,
respectively, compared with 96% and 77% in the prior year periods.

         Cost of sales  decreased  to $44,000  and $84,000 for the three and six
months ended June 30, 1999,  respectively,  from $676,000 and $1,512,000 for the
same periods in the prior year.  The 93% and 94%  decreases in cost of sales for
the second and first quarters of 1999,  respectively  are due to the elimination
of manufacturing  operations combined with lower unit shipments of the company's
T-TAC and ERA products.

         Research and development  ("R&D") expenses,  which include clinical and
regulatory  expenses,  decreased to $1,013,000  and $1,751,000 for the three and
six months ended June 30, 1999, respectively, from $1,563,000 and $2,949,000 for
the same periods in the prior year.  The 35% and 40% decreases for the three and
six months ending June 30, 1999 are primarily due to a reduced level of research
and development activities on the Company's STARRT and ERA product lines.

         Selling,  general and  administrative  ("SG&A")  expenses  decreased to
$710,000  and  $1,262,000  for the three and six  months  ended  June 30,  1999,
respectively,  from  $2,042,000 and $3,819,000 for the same periods in the prior
year. The 65% and 66% decreases, respectively, are due to the elimination of all
sales and  marketing  personnel and reduced  administrative  overhead due to the
restructuring in July 1998.

         Net interest and  investment  income  decreased to $230,000 and $448,00
for the three and six months ended June 30, 1999,  respectively,  from  $333,000
and $709,000 for the same periods in the prior year. The decreases for the three
and six months ended June 30, 1999 are a result of lower  average cash  balances
due to the  utilization of cash for operations.  Interest  expense for the three
and six  months  ended  June 30,  1999 and the  amount  for the same  respective
periods in the prior year are immaterial.

         As a  result  of the  items  discussed  above,  net loss  increased  to
$1,499,000  and  $2,581,000  for the three and six months  ended June 30,  1999,
respectively,  from $3,863,000 and $7,319,000 for the same respective periods in
1998.

                                       9
<PAGE>

         The Company has a limited history of operations. Since its inception in
September  1992,  the  Company  has  been  engaged  primarily  in  research  and
development of its T-TAC and STARRT  Falloposcopy  systems and its S/TOP device,
and since 1996, the ERA and FUTURA product lines. The Company has generated only
limited revenues and has only limited experience in manufacturing,  marketing or
selling  its  products in  commercial  quantities.  The Company has  experienced
significant  operating  losses since  inception and, as of June 30, 1999, had an
accumulated deficit of $48 million.  The Company expects its operating losses to
continue  for at  least  the  next  several  years  as it  continues  to  expend
substantial  resources in research and product  development and funding clinical
trials in support of its S/TOP  device.  Due to the  expense  and  unpredictable
nature of these  activities,  there can be no  assurance  that the Company  will
achieve or sustain profitability in the future.


Liquidity and Capital Resources

         At June 30, 1999,  Conceptus had cash, cash equivalents and investments
of $14.7 million, compared with $17.1 million at December 31, 1998. The decrease
is  primarily  due  to  $2.4  million  used  in  operating  activities.  Capital
expenditures  for the  first  half of 1999  decreased  to $9,000  compared  with
capital expenditures of $718,000 in the prior year period.  Capital expenditures
in the  first  half  of 1999  represent  the  purchase  of  additional  computer
equipment required for research and development, whereas capital expenditures in
the first half of 1998 represent leasehold improvements, furniture and equipment
for a new facility which has been leased to a third party through 2003.

         Conceptus   believes  that  its  existing  capital  resources  will  be
sufficient to fund its operations  through 2000.  However,  the Company's future
liquidity and capital requirements will depend upon numerous factors,  including
the  progress  of  the  Company's  clinical  research  and  product  development
programs,  the receipt of and the time required to obtain regulatory  clearances
and  approvals,  and the  resources  devoted to developing  the Company's  S/TOP
product.  Accordingly,  there  can be no  assurance  that the  Company  will not
require additional  financing within this time frame and, therefore,  may in the
future seek to raise additional  funds through bank  facilities,  debt or equity
offerings  or other  sources of  capital.  Furthermore,  any  additional  equity
financing may be dilutive to stockholders, and debt financing, if available, may
involve  restrictive  convenants.  Additional  funding may not be available when
needed or on terms  acceptable  to the  Company,  which  would  have a  material
adverse effect on the Company.

         The "Year 2000 issue" arises because most computer systems and programs
were  designed to handle only a two-digit  year,  not a four-digit  year.  These
computer  systems and  programs  may  interpret  "00" as the year 1900 and could
either  stop  processing   date-related   computations  or  could  process  them
incorrectly in the year 2000.  The Company has been informed by its  information
system  vendors that such  systems are able to process the year 2000  accurately
and  accordingly  does  not  anticipate  any  Year  2000  issues  from  its  own
information  systems,  databases  or  programs.  However,  the Company  could be
adversely impacted by Year 2000 issues faced by major  distributors,  suppliers,
customers,  vendors and financial service  organizations  with which the Company
interacts.  The Company is in the process of  developing a plan to determine the
impact  that third  parties  which are not Year 2000  compliant  may have on the
operations of the Company. There can be no assurance that such plan will be able
to address  fully,  or at all, the impact of the Year 2000 issue on the Company,
which  could  have a  material  adverse  effect  upon  the  Company's  business,
financial condition and results of operations.


Item 3.  Quantitative and Qualitative Disclosures About Market Risk

         Not applicable.

                                       10

<PAGE>


                           Part II. Other Information


Item 1.  Legal Proceedings

         There are no material pending or threatened legal  proceedings  against
the Company.  The Company from time to time is involved in routine legal matters
incident to its  business.  While  management  currently  believes the amount of
ultimate  liability,  if any, with respect to these actions will not  materially
affect the  financial  position,  results of  operations,  or  liquidity  of the
Company, the ultimate outcome of any litigation is uncertain.


Item 2.  Changes in Securities

         None.

Item 3.  Defaults in Senior Securities

         None.

Item 4.  Submission of Matters to a Vote of Security Holders

         None.

Item 5.  Other Information

         None.

Item 6.  Exhibits and Reports on Form 8-K

        (a)      Exhibit 27

                 Exhibit 27        Financial Data Schedule

        (a)      Reports on Form 8-K.

                 None.

                                       11


<PAGE>


                                           SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                 CONCEPTUS, INC.


                                 By: /s/             OLIVER BROUSE
                                 -----------------------------------------------
                                                     Oliver Brouse
                                                  Director of Finance
                                        (Duly Authorized and Principal Financial
                                                and Accounting Director)


Date:    August 13, 1999

                                       12

<PAGE>


                                INDEX TO EXHIBITS


      Exhibit
      Number                                     Description
      ------                                     -----------
         27                               Financial Data Schedule






                                       13